Hansoh Pharmaceutical (03692) Announces NMPA Approval for Clinical Trials of HS-20197 Injection for Advanced Solid Tumors

Hansoh Pharma(03692) announced that on September 11, 2026, the Group’s independently developed Class 1 new drug, HS-20197 for injection, received the Notice of Approval for Drug Clinical Trials issued by the National Medical Products Administration (NMPA) of China, intended for conducting clinical trials in “advanced solid tumors.”